137 related articles for article (PubMed ID: 12421285)
1. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
Yildiran ST; Fothergill AW; Sutton DA; Rinaldi MG
Mycoses; 2002 Nov; 45(9-10):378-83. PubMed ID: 12421285
[TBL] [Abstract][Full Text] [Related]
2. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
4. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
Pfaller MA; Zhang J; Messer SA; Brandt ME; Hajjeh RA; Jessup CJ; Tumberland M; Mbidde EK; Ghannoum MA
Antimicrob Agents Chemother; 1999 Jan; 43(1):169-71. PubMed ID: 9869586
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
[TBL] [Abstract][Full Text] [Related]
7. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
9. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.
Yildiran ST; Saracli MA; Fothergill AW; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 2000 Apr; 19(4):317-9. PubMed ID: 10834825
[TBL] [Abstract][Full Text] [Related]
12. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.
Nguyen MH; Yu CY
Antimicrob Agents Chemother; 1998 Feb; 42(2):471-2. PubMed ID: 9527812
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
Thompson GR; Wiederhold NP; Fothergill AW; Vallor AC; Wickes BL; Patterson TF
Antimicrob Agents Chemother; 2009 Jan; 53(1):309-11. PubMed ID: 18955539
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
Chandenier J; Adou-Bryn KD; Douchet C; Sar B; Kombila M; Swinne D; Thérizol-Ferly M; Buisson Y; Richard-Lenoble D
Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):506-8. PubMed ID: 15141336
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.
Hoban DJ; Zhanel GG; Karlowsky JA
Antimicrob Agents Chemother; 1999 Jun; 43(6):1463-4. PubMed ID: 10348771
[TBL] [Abstract][Full Text] [Related]
16. Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole.
Khan ZU; Randhawa HS; Chehadeh W; Chowdhary A; Kowshik T; Chandy R
Int J Antimicrob Agents; 2009 Jun; 33(6):559-63. PubMed ID: 19195846
[TBL] [Abstract][Full Text] [Related]
17. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
18. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii.
Torres-Rodríguez JM; Alvarado-Ramírez E; Murciano F; Sellart M
J Antimicrob Chemother; 2008 Jul; 62(1):205-6. PubMed ID: 18375969
[No Abstract] [Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.
Yamazumi T; Pfaller MA; Messer SA; Houston A; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2000 Oct; 44(10):2883-6. PubMed ID: 10991880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
